Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and ABL Bio Inc. announced a collaboration to develop new Bispecific antibody-drug conjugates (bsADCs). Biocytogen's RenLite®? mice platform can produce fully human antibodies with diverse epitopes and high affinity.

This platform is notable for its ability to generate antibodies in a common light chain format, offering a distinct combination of design flexibility, simplified manufacturing processes, and optimal developability for bsADC development. Based on this platform, both companies will be able to discuss expanding their collaboration for various types of ADC development.